BASIC SALE AND PURCHASE AGREEMENTBasic Sale and Purchase Agreement • November 9th, 2021 • Harrow Health, Inc. • Pharmaceutical preparations • Delaware
This BASIC SALE AND PURCHASE AGREEMENT (hereinafter referred to as this “Agreement”) made and entered into this 18th day of August, 2021 (hereinafter referred to as the “Effective Date”), by and between WAKAMOTO PHARMACEUTICAL CO., LTD., a corporation duly incorporated and existing under the laws of Japan, having its principal place of business at 2-2, Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo, 103-8330 Japan (hereinafter referred to as “Wakamoto”) and Harrow Health, Inc., a corporation organized and existing under the laws of State of Delaware, having its principal place of business at 102 Woodmont Blvd., Suite 610, Nashville, TN 37205 USA (hereinafter referred to as “Harrow”),
LICENSE AGREEMENT BY AND BETWEEN WAKAMOTO PHARMACEUTICAL CO., LTD. AND HARROW HEALTH, INC. AUGUST 18, 2021 LICENSE AGREEMENTLicense Agreement • November 9th, 2021 • Harrow Health, Inc. • Pharmaceutical preparations • Harrow
This License Agreement (this “Agreement”) is made effective as of the day of August, 2021 (the “Effective Date”) by and between Wakamoto Pharmaceutical Co., Ltd. Japanese corporation having its principal place of business at 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8330, Japan, including its Affiliates (“Wakamoto”), and Harrow Health, Inc., a Delaware corporation having its principal place of business at 102 Woodmont Blvd., Suite 610, Nashville, TN 37205 USA, including its Affiliates (“Harrow”). Wakamoto and Harrow are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
